FY2026 EPS Estimates for Dare Bioscience Raised by Analyst

Dare Bioscience, Inc. (NASDAQ:DARE) – Investment analysts at Brookline Capital Markets increased their FY2026 earnings per share estimates for Dare Bioscience in a report issued on Friday, May 15th. Brookline Capital Markets analyst K. Dolliver now forecasts that the biotechnology company will earn ($1.37) per share for the year, up from their previous estimate of ($1.50). The consensus estimate for Dare Bioscience’s current full-year earnings is ($1.50) per share. Brookline Capital Markets also issued estimates for Dare Bioscience’s Q4 2026 earnings at ($0.38) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Dare Bioscience Stock Performance

Shares of DARE stock opened at $2.11 on Tuesday. The stock’s fifty day moving average is $2.00 and its 200-day moving average is $1.92. The stock has a market capitalization of $31.61 million, a PE ratio of -2.22 and a beta of 1.09. Dare Bioscience has a 52 week low of $1.27 and a 52 week high of $9.19.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.13. The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.03 million.

Hedge Funds Weigh In On Dare Bioscience

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Dare Bioscience in the third quarter valued at about $37,000. Raymond James Financial Inc. boosted its holdings in Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 13,650 shares during the last quarter. Finally, LPL Financial LLC bought a new position in Dare Bioscience in the fourth quarter valued at about $28,000. Institutional investors own 6.70% of the company’s stock.

Dare Bioscience News Summary

Here are the key news stories impacting Dare Bioscience this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Dare Bioscience, suggesting slightly improved near-term expectations for the women’s health biotech. DARE stock page
• Positive Sentiment: HC Wainwright’s long-range outlook was constructive, with estimates showing a path to profitability in later years, including positive EPS projected for FY2028 and FY2029. DARE stock page
• Neutral Sentiment: The company announced it has started a Phase 2 study of DARE-HPV, a treatment for persistent high-risk HPV infection, backed by a $10 million ARPA-H-funded contract. The trial is an important pipeline update, but topline data is not expected until 2027, so the near-term stock impact is likely limited. Article: Daré Bioscience Initiates Phase 2 Study of DARE-HPV
• Negative Sentiment: Several analyst updates still point to expected losses in 2026 and 2027, reinforcing that Dare Bioscience remains far from consistent profitability. DARE stock page

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.